GlaxoSmithKline plans to expand its manufacturing facility in Mississauga, Ontario, in part to enable production of Relenza zanamivir dry powder for inhalation. The expansion is expected to create 70 new jobs. GSK will contribute more than $30 million, with the province of Ontario kicking in $3.6 million.
Paul Lucas, President and CEO of GlaxoSmithKline Inc. said, “Today’s announcement reflects a shared commitment to biopharmaceutical innovation and advanced manufacturing by GSK and the Ontario government. I am proud of the role that GSK in Canada is playing in improving lives around the world, which is now enhanced as a result of this partnership.”
GSK currently employs more than 1,150 people in the province.
Read the GSK press release.
